📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. (2021)

First Author: O'Connor MN

Attributed to: A Phase I/IIa Clinical Trial of a Humanised Monoclonal Antibody Against LRG1 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.medj.2021.10.002

PubMed Identifier: 35590198

Publication URI: http://europepmc.org/abstract/MED/35590198

Type: Journal Article/Review

Volume: 2

Parent Publication: Med (New York, N.Y.)

Issue: 11

ISSN: 2666-6340